公开(公告)号：US10064835B2

公开(公告)日：2018-09-04

申请号：US14371905

申请日：2013-01-10

Applicant: ABBOTT LABORATORIES

Inventor： Jeffrey L. Nelson ,  Anne C. Voss ,  Maria G. Baggs ,  Charles L. Paule ,  Refaat A. Hegazi ,  Fabrizis Suarez ,  Gary Fanjiang

IPC: A01N37/02 ,  A61K31/22 ,  A61K31/19 ,  A61K31/198 ,  A61K9/00 ,  A61K9/127 ,  A23L33/10 ,  A23L33/175

Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.

公开(公告)号：US20150133548A1

公开(公告)日：2015-05-14

申请号：US14371905

申请日：2013-01-10

Applicant: ABBOTT LABORATORIES

Inventor： Jeffrey L. Nelson ,  Anne C. Voss ,  Maria G. Baggs ,  Charles L. Paule ,  Refaat A. Hegazi ,  Fabrizis Suarez ,  Gary Fanjiang

IPC: A61K31/22 ,  A23L1/30 ,  A23L1/305 ,  A61K31/198

CPC classification number: A61K31/22 ,  A23L33/10 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1272 ,  A61K31/19 ,  A61K31/198 ,  A61K2300/00

Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.

Abstract translation: 公开了用于治疗糖尿病个体中的糖尿病性溃疡的方法中的β-羟基-β-甲基丁酸酯，精氨酸和谷氨酰胺的组合，其具有以下至少一种：（a）血清白蛋白水平小于或等于 4.0g / dL，和/或（b）小于1.0的踝臂指数。 还公开了β-羟基-β-甲基丁酸酯，精氨酸和谷氨酰胺的组合在制备用于治疗糖尿病患者中的糖尿病性溃疡的药物中的用途，其具有以下至少一种：（a ）血清白蛋白水平小于或等于4.0g / dL，和/或（b）小于1.0的踝臂指数。 在某些实施方案中，通过营养组合物口服施用β-羟基-β-甲基丁酸酯，精氨酸和谷氨酰胺的组合。